response-adapted radiation

RADIATION2 trials

Sponsors

Children's Cancer Group, China, Fudan University

Conditions

AdolescentBrentuximab VedotinChildClassical Hodgkin LymphomaLymphoma, B-Cell, Marginal ZoneMetabolic ResponsePET ScanSurvival

Phase 2

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

RecruitingNCT06563245

Children's Cancer Group, ChinaAdolescent, Brentuximab Vedotin, Child +6

Start: 2024-09-25End: 2039-11-15Target: 96Updated: 2026-03-19

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

Active, not recruitingNCT06583837

Fudan UniversityLymphoma, B-Cell, Marginal Zone

Start: 2024-09-10End: 2027-09-01Updated: 2026-02-27